NRX Pharmaceuticals, Inc. (NRXP) income statement
NRXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$2.80+0.35 (+14.29%)
Close on Nov 18, 2026Market cap $121.23MP/E –Yield –
NRX Pharmaceuticals, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 46.6%
- Operating margin
- -586.2%
- Net margin
- -691.8%
- Return on equity, FY2025
- 146.2%
Financial strength
- Current ratio
- 0.86
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 78.8%
Valuation
- P/E ratio
- –
- Price to sales
- 35.72
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?